Third International Stroke Trial 3
Third International Stroke Trial 3
IST-3 recruited 1007 patients between 4.5 and 6 h of onset. The effect seen in this subgroup was consistent with a small but potentially worthwhile clinical benefit, but the trial lacked statistical power to reliably determine the 'latest time for clinical benefit' either alone or in the summary data meta-analysis by Wardlaw. However, the Stroke Thrombolysis Trialists Collaboration is undertaking an independent individual patient data meta-analysis of all the i.v. rt-PA trials, which will have greater statistical power to assess the precise duration of the therapeutic time window for i.v. thrombolytic therapy (and also to assess what factors might modify the response to treatment).
Is Intravenous Thrombolysis Safe and Effective Beyond 4.5 H?
IST-3 recruited 1007 patients between 4.5 and 6 h of onset. The effect seen in this subgroup was consistent with a small but potentially worthwhile clinical benefit, but the trial lacked statistical power to reliably determine the 'latest time for clinical benefit' either alone or in the summary data meta-analysis by Wardlaw. However, the Stroke Thrombolysis Trialists Collaboration is undertaking an independent individual patient data meta-analysis of all the i.v. rt-PA trials, which will have greater statistical power to assess the precise duration of the therapeutic time window for i.v. thrombolytic therapy (and also to assess what factors might modify the response to treatment).
Source...